Featured Research

from universities, journals, and other organizations

Reducing the toxicity of lithium

Date:
June 10, 2010
Source:
Journal of Clinical Investigation
Summary:
Lithium is the most effective treatment for bipolar disorder. However, its use is limited because of neurological side effects and a risk for overdose-induced toxicity. Researchers have now delineated a molecular pathway by which chronic administration of therapeutic doses of lithium has negative effects in mice and hope that these data might provide new ideas for combination therapies that diminish the toxicities of lithium.

Lithium is the most effective treatment for bipolar disorder. However, its use is limited because of neurological side effects and a risk for overdose-induced toxicity. Many of the beneficial effects of lithium are mediated by its inhibition of GSK-3 proteins, but whether this is the mechanism underlying its negative effects has not been determined.

However, Raquel Gσmez-Sintes and Josι Lucas, at CSIC/UAM, Spain, have now delineated a molecular pathway by which chronic administration of therapeutic doses of lithium has negative effects in mice.

Specifically, they found that gait abnormalities and nerve cell death in several regions of the brain were a result of GSK-3 protein inhibition, which led to increased nuclear localization of NFATc3/4 proteins and increased levels of the death-inducing molecule Fas ligand.

The authors hope that these data might provide new ideas for combination therapies that diminish the toxicities of lithium, which has been proposed as a treatment for Alzheimer disease.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. Raquel Gσmez-Sintes and Josι J. Lucas. NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy. Journal of Clinical Investigation, June 7, 2010 DOI: 10.1172/JCI37873

Cite This Page:

Journal of Clinical Investigation. "Reducing the toxicity of lithium." ScienceDaily. ScienceDaily, 10 June 2010. <www.sciencedaily.com/releases/2010/06/100607192718.htm>.
Journal of Clinical Investigation. (2010, June 10). Reducing the toxicity of lithium. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/06/100607192718.htm
Journal of Clinical Investigation. "Reducing the toxicity of lithium." ScienceDaily. www.sciencedaily.com/releases/2010/06/100607192718.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins